4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶
中文名称:
4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶
中文同义词:
4-氨基-1-环戊基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶;化合物PCI29732
英文名称:
PCI 29732
英文同义词:
PCI 29732;4-Amino-1-cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine;1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;PCI 29732 (This product is only available in Japan.);CS-2698;PCI 29732;PCI29732;PCI-29732;1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-cyclopentyl-3-(4-phenoxyphenyl)-
CAS号:
330786-25-9
分子式:
C22H21N5O
分子量:
371.43
EINECS号:
相关类别:
Mol文件:
330786-25-9.mol
沸点
599.6±50.0 °C(Predicted)
密度
1.36±0.1 g/cm3(Predicted)
酸度系数(pKa)
4.24±0.30(Predicted)
CAS 数据库
330786-25-9
生物活性
PCI 29732是一种选择性的、不可逆的Btk抑制剂，IC50为0.5 nM。
靶点
Target Value
BTK
(Cell-free assay) 0.5 nM
BLK
(Cell-free assay) 0.5 nM
Bmx
(Cell-free assay) 0.8 nM
EGFR
(Cell-free assay) 5.6 nM
YES
(Cell-free assay) 6.5 nM
Target
Value
BTK
(Cell-free assay)
0.5 nM
BLK
(Cell-free assay)
0.5 nM
Bmx
(Cell-free assay)
0.8 nM
EGFR
(Cell-free assay)
5.6 nM
YES
(Cell-free assay)
6.5 nM
体外研究
PCI29732 shows cytotoxicity in different cells. The IC 50 values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells.
PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).
体内研究
PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents.
PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.
Animal Model: 5-6 weeks old athymic nude mice (bearing H460/MX20 cells)
Dosage: 20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration)
Administration: P.o.; every 3 d × 5 times
Result: Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.
Animal Model:
5-6 weeks old athymic nude mice (bearing H460/MX20 cells)
Dosage:
20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p., 3 mg/kg; topotecan was given 1 h after PCI29732 administration)
Administration:
P.o.; every 3 d × 5 times
Result:
Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.
